1
|
Carbone A, Verrienti A, Cito DS, Sponziello M, Pecce V, Bruno R. Effective TRIAC treatment of a THRβ-mutated patient with thyroid hormone resistance. Endocrine 2024:10.1007/s12020-024-03795-3. [PMID: 38558372 DOI: 10.1007/s12020-024-03795-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Accepted: 03/20/2024] [Indexed: 04/04/2024]
Abstract
Resistance to thyroid hormone (RTH) is a rare autosomal dominant disease characterized by an alteration of thyroid hormone negative feedback, usually as a consequence of a mutation in the thyroid hormone receptor-b gene (THRβ). It is characterized by high variability of clinical manifestations, ranging from isolated abnormal thyroid function tests without symptoms to severe and impaired clinical conditions. Here we report the case of a woman who was diagnosed with RTHβ when she was 35 years old and was treated with 3,5,3-triiodiothyroacetic acid (TRIAC) because of the onset of clinical symptoms of hyperthyroidism. This therapy has been effective in controlling thyrotoxicosis for 5 years. After this time the patient developed an autoimmune hyperthyroidism, with TSH receptor autoantibodies appearance, which caused a loss of efficacy of the drug in controlling the disease. The development of different pathophysiological mechanisms of thyrotoxicosis, as in this case, could be the reason for both variability of disease manifestations and of loss of response to drug therapy.
Collapse
Affiliation(s)
- A Carbone
- Endocrine Unit- Asm Matera, Rome, Italy
| | - A Verrienti
- Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - D S Cito
- Endocrine Unit- Asm Matera, Rome, Italy
| | - M Sponziello
- Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - V Pecce
- Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - R Bruno
- Endocrine Unit- Asm Matera, Rome, Italy.
| |
Collapse
|
2
|
Acampora R, de Falco A, Lanfranchi F, Montella S, Scala R, Lieto M, Durante L, Bruno R. Delayed onset Bickerstaff brainstem encephalitis overlapping Miller-Fisher Syndrome during SARS-CoV-2 infection. Neurol Sci 2023; 44:4179-4182. [PMID: 37889381 DOI: 10.1007/s10072-023-07142-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Accepted: 10/17/2023] [Indexed: 10/28/2023]
Abstract
Bickerstaff brainstem encephalitis (BBE) is a neuroimmunologic disease characterized by the acute onset of external ophthalmoplegia, ataxia, and consciousness disturbance, mostly subsequent to an infection. BBE is considered to be a variant of Miller-Fisher syndrome (MFS), which also exhibits external ophthalmoplegia and ataxia but not presenting consciousness alterations. Therefore, these two medical conditions are included in the clinical spectrum of the "Fisher-Bickerstaff syndrome" ( Shahrizaila and Yuki in J Neurol Neurosurg Psychiatry 84(5):576-583) [1]. With regard to the etiopathogenesis, increasing evidence worldwide suggests that SARS-CoV-2 infection-enhanced immune response is involved in a wide range of neurological complications such as Guillain-Barré syndrome (GBS), MFS, acute necrotizing encephalitis (ANE), myelitis, acute disseminated encephalomyelitis (ADEM), and, although very rarely, BBE either (Hosseini et al. in Rev Neurosci 32:671-691) [2]. We report a case of a patient affected by delayed onset BBE overlapping MFS during a mild SARS-CoV-2 infection. To the best of our knowledge, similar cases have never been reported.
Collapse
Affiliation(s)
- R Acampora
- Department of Neurology and Stroke Unit, Ospedale del Mare Hospital, Naples, Italy.
| | - A de Falco
- Department of Neurology and Stroke Unit, Ospedale del Mare Hospital, Naples, Italy
| | - F Lanfranchi
- Department of Health Sciences (DISSAL), University of Genoa, 16132, Genoa, Italy
| | - S Montella
- Department of Neurology and Stroke Unit, Ospedale del Mare Hospital, Naples, Italy
| | - R Scala
- Department of Neurology and Stroke Unit, Ospedale del Mare Hospital, Naples, Italy
| | - M Lieto
- Department of Neurology and Stroke Unit, Ospedale del Mare Hospital, Naples, Italy
| | - L Durante
- Department of Neurology and Stroke Unit, Ospedale del Mare Hospital, Naples, Italy
| | - R Bruno
- Department of Neurology and Stroke Unit, Ospedale del Mare Hospital, Naples, Italy
| |
Collapse
|
3
|
Pedrazzoli P, Lasagna A, Cassaniti I, Piralla A, Squeri A, Bruno R, Sacchi P, Baldanti F, Di Maio M, Beretta GD, Cinieri S, Silvestris N. Vaccination for seasonal flu, pneumococcal infection, and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM). ESMO Open 2023; 8:101215. [PMID: 37104930 PMCID: PMC10067463 DOI: 10.1016/j.esmoop.2023.101215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Revised: 03/13/2023] [Accepted: 03/22/2023] [Indexed: 04/05/2023] Open
Abstract
Patients with cancer have a well-known and higher risk of vaccine-preventable diseases (VPDs). VPDs may cause severe complications in this setting due to the immune system impairment, malnutrition and oncological treatments. Despite this evidence, vaccination rates are inadequate. The Italian Association of Medical Oncology (AIOM) has been involved in vaccination awareness since 2014. Based on a careful review of the available data about the immunogenicity, effectiveness and safety of flu, pneumococcal and anti-SARS-CoV-2 vaccines, we report the recommendations of the Associazione Italiana di Oncologia Medica about these vaccinations in adult patients with solid tumors. AIOM recommends comprehensive education on the issue of VPDs. We believe that a multidisciplinary care model may improve the vaccination coverage in immunocompromised patients. Continued surveillance, implementation of preventive practices and future well-designed immunological prospective studies are essential for a better management of our patients with cancer.
Collapse
Affiliation(s)
- P Pedrazzoli
- Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - A Lasagna
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
| | - I Cassaniti
- Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - A Piralla
- Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - A Squeri
- Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy; School of Specialization in Medical Oncology, University of Messina, Messina, Italy
| | - R Bruno
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - P Sacchi
- Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - F Baldanti
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - M Di Maio
- Department of Oncology, University of Turin, Division of Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy
| | - G D Beretta
- Medical Oncology Unit, Santo Spirito Hospital, Pescara, Italy
| | - S Cinieri
- Medical Oncology Division and Breast Unit, Senatore Antonio Perrino Hospital, ASL Brindisi, Brindisi, Italy
| | - N Silvestris
- Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy
| |
Collapse
|
4
|
Oehler D, Immohr MB, Bruno R, Sigetti D, Haschemi J, Aubin H, Tudorache I, Westenfeld R, Bönner F, Kelm M, Lichtenberg A, Boeken U. Treatment and Outcome of COVID-19 after Heart Transplantation: Update from a German Transplant Center. Thorac Cardiovasc Surg 2023. [DOI: 10.1055/s-0043-1761750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023]
Affiliation(s)
- D. Oehler
- Department of Cardiology, Pulmonology, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
| | - M. B. Immohr
- Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
| | - R. Bruno
- Department of Cardiology, Pulmonology, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
| | - D. Sigetti
- Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
| | - J. Haschemi
- Department of Cardiology, Pulmonology, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
| | - H. Aubin
- Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
| | - I. Tudorache
- Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
| | - R. Westenfeld
- Department of Cardiology, Pulmonology, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
| | - F. Bönner
- Department of Cardiology, Pulmonology, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
| | - M. Kelm
- Department of Cardiology, Pulmonology, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
| | - A. Lichtenberg
- Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
| | - U. Boeken
- Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University, Düsseldorf, Deutschland
| |
Collapse
|
5
|
Oehler D, Immohr M, Boettger C, Erbel-Khurtsidze S, Aubin H, Bruno R, Holst T, Horn P, Westenfeld R, Kelm M, Tudorache I, Akhyari P, Lichtenberg A, Boeken U. Donor hypernatremia is associated with increased mortality after heart transplantation. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Objective
Donor hypernatremia has been associated with primary graft dysfunction in heart transplantation and is known to be associated with impaired outcome following liver and renal transplantation. However, controversial data exist regarding the impact of sodium deregulation in patient survival after heart transplantation (HTx). This study aims to investigate the impact of donor sodium levels on early morbidity and short- and midterm survival following HTx.
Methods
Between September 2010 and June 2021, a total of n=218 patients underwent HTx in our centre. From those, 214 could be included retrospectively in our study. For each donor, sodium levels were collected and different cut-off levels from 145 to 159 mmol/l were investigated by Kaplan-Meier-analysis. Then, recipients were divided in three groups regarding donor sodium: Normonatremia (133–145 mmol/l, n=73), mild hypernatremia (146–156 mmol/l, n=105) and severe hypernatremia (>156 mmol/l, n=35). Recipient and donor variables were reviewed and compared, including peri- and postoperative characteristics and recipient survival after up to 5 years after transplantation.
Results
All patients were comparable regarding baseline characteristics and perioperative parameters. Regarding early mortality, 90-day survival was significantly reduced only in patients with severe donor hypernatremia in comparison to normonatremia (see table 1 and fifgure 1, 90% vs. 71%, p=0.02), but not in mild normonatremia (89%, p=0.89). 1-year survival was comparable in all groups (p>0.28).
Conclusion
Donor hypernatremia was associated with reduced short-term survival, while correlation weakens >1 year after HTx. Future prospective studies are needed to confirm the possible cut-off value of 156 mmol/l for donor-acceptancy.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- D Oehler
- University Hospital Duesseldorf, Department of Cardiology, Pulmonology and Vascular Medicine , Duesseldorf , Germany
| | - M Immohr
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| | - C Boettger
- University Hospital Duesseldorf, Department of Diagnostic and Interventional Radiology , Duesseldorf , Germany
| | - S Erbel-Khurtsidze
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| | - H Aubin
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| | - R Bruno
- University Hospital Duesseldorf, Department of Cardiology, Pulmonology and Vascular Medicine , Duesseldorf , Germany
| | - T Holst
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| | - P Horn
- University Hospital Duesseldorf, Department of Cardiology, Pulmonology and Vascular Medicine , Duesseldorf , Germany
| | - R Westenfeld
- University Hospital Duesseldorf, Department of Cardiology, Pulmonology and Vascular Medicine , Duesseldorf , Germany
| | - M Kelm
- University Hospital Duesseldorf, Department of Cardiology, Pulmonology and Vascular Medicine , Duesseldorf , Germany
| | - I Tudorache
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| | - P Akhyari
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| | - A Lichtenberg
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| | - U Boeken
- University Hospital Duesseldorf, Department of Cardiac Surgery , Duesseldorf , Germany
| |
Collapse
|
6
|
Verrienti A, Carbone A, Sponziello M, Pecce V, Cito DS, Bruno R. Papillary thyroid carcinoma as first and isolated neoplastic disease in a Lynch syndrome family member with a germline MLH1 mutation. Endocrine 2022; 77:199-202. [PMID: 35415788 DOI: 10.1007/s12020-022-03048-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Accepted: 03/22/2022] [Indexed: 11/03/2022]
Affiliation(s)
- A Verrienti
- Department of Translational and Precision Medicine, Sapienza University, 00185, Rome, Italy
| | - A Carbone
- Endocrine Unit, Tinchi Hospital, 75015, Matera, Italy
| | - M Sponziello
- Department of Translational and Precision Medicine, Sapienza University, 00185, Rome, Italy
| | - V Pecce
- Department of Translational and Precision Medicine, Sapienza University, 00185, Rome, Italy
| | - D S Cito
- Endocrine Unit, Tinchi Hospital, 75015, Matera, Italy
| | - R Bruno
- Endocrine Unit, Tinchi Hospital, 75015, Matera, Italy.
| |
Collapse
|
7
|
Boettger C, Immohr MB, Mehdiani A, Akhyari P, Aubin H, Tudorache I, Bruno R, Westenfeld R, Lichtenberg A, Boeken U. Does the Duration of Donor-Stay on ICU Impact the Outcome after Heart Transplantation? Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- C. Boettger
- Department of Cardiac Surgery, Medical Faculty, University Hospital of the Heinrich-Heine University, Düsseldorf, Deutschland
| | - M. B. Immohr
- Department of Cardiac Surgery, Medical Faculty, University Hospital of the Heinrich-Heine University, Düsseldorf, Deutschland
| | - A. Mehdiani
- Department of Cardiac Surgery, Medical Faculty, University Hospital of the Heinrich-Heine University, Düsseldorf, Deutschland
| | - P. Akhyari
- Department of Cardiac Surgery, Medical Faculty, University Hospital of the Heinrich-Heine University, Düsseldorf, Deutschland
| | - H. Aubin
- Department of Cardiac Surgery, Medical Faculty, University Hospital of the Heinrich-Heine University, Düsseldorf, Deutschland
| | - I. Tudorache
- Department of Cardiac Surgery, Medical Faculty, University Hospital of the Heinrich-Heine University, Düsseldorf, Deutschland
| | - R. Bruno
- Department of Cardiology, Medical Faculty, University Hospital of the Heinrich-Heine University, Düsseldorf, Deutschland
| | - R. Westenfeld
- Department of Cardiology, Medical Faculty, University Hospital of the Heinrich-Heine University, Düsseldorf, Deutschland
| | - A. Lichtenberg
- Department of Cardiac Surgery, Medical Faculty, University Hospital of the Heinrich-Heine University, Düsseldorf, Deutschland
| | - U. Boeken
- Department of Cardiac Surgery, Medical Faculty, University Hospital of the Heinrich-Heine University, Düsseldorf, Deutschland
| |
Collapse
|
8
|
Oehler D, Immohr MB, Erbel S, Aubin H, Bruno R, Holst HT, Westenfeld R, Horn P, Tudorache I, Akhyari P, Lichtenberg A, Boeken U. Intracerebral Bleeding in Donors Is Associated with Worsened Outcome and Reduced Short- to Midterm Survival of Heart Transplant Recipients. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- D. Oehler
- Department of Cardiology, Medical faculty, University Hospital of the Heinrich-Heine-University, Duesseldorf, Deutschland
| | - M. B. Immohr
- Department of Cardiac Surgery, Medical faculty, University Hospital of the Heinrich-Heine-University, Duesseldorf, Deutschland
| | - S. Erbel
- Department of Cardiac Surgery, Medical faculty, University Hospital of the Heinrich-Heine-University, Duesseldorf, Deutschland
| | - H. Aubin
- Department of Cardiac Surgery, Medical faculty, University Hospital of the Heinrich-Heine-University, Duesseldorf, Deutschland
| | - R. Bruno
- Department of Cardiology, Medical faculty, University Hospital of the Heinrich-Heine-University, Duesseldorf, Deutschland
| | - H. T. Holst
- Department of Cardiac Surgery, Medical faculty, University Hospital of the Heinrich-Heine-University, Duesseldorf, Deutschland
| | - R. Westenfeld
- Department of Cardiology, Medical faculty, University Hospital of the Heinrich-Heine-University, Duesseldorf, Deutschland
| | - P. Horn
- Department of Cardiology, Medical faculty, University Hospital of the Heinrich-Heine-University, Duesseldorf, Deutschland
| | - I. Tudorache
- Department of Cardiac Surgery, Medical faculty, University Hospital of the Heinrich-Heine-University, Duesseldorf, Deutschland
| | - P. Akhyari
- Department of Cardiac Surgery, Medical faculty, University Hospital of the Heinrich-Heine-University, Duesseldorf, Deutschland
| | - A. Lichtenberg
- Department of Cardiac Surgery, Medical faculty, University Hospital of the Heinrich-Heine-University, Duesseldorf, Deutschland
| | - U. Boeken
- Department of Cardiac Surgery, Medical faculty, University Hospital of the Heinrich-Heine-University, Duesseldorf, Deutschland
| |
Collapse
|
9
|
Kerioui M, Desmée S, Mercier F, Lin A, Wu B, Jin JY, Shen X, Le Tourneau C, Bruno R, Guedj J. Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy. ESMO Open 2021; 7:100346. [PMID: 34954496 PMCID: PMC8718952 DOI: 10.1016/j.esmoop.2021.100346] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 09/23/2021] [Accepted: 11/22/2021] [Indexed: 12/26/2022] Open
Abstract
Background Tumor dynamics typically rely on the sum of the longest diameters (SLD) of target lesions, and ignore heterogeneity in individual lesion dynamics located in different organs. Patients and methods Here we evaluated the benefit of analyzing lesion dynamics in different organs to predict survival in 900 patients with metastatic urothelial carcinoma treated with atezolizumab or chemotherapy (IMvigor211 trial). Results Lesion dynamics varied largely across organs, with lymph nodes and lung lesions showing on average a better response to both treatments than those located in the liver and locoregionally. A benefit of atezolizumab was observed on lung and liver lesion dynamics that was attributed to a longer duration of treatment effect as compared to chemotherapy (P value = 0.043 and 0.001, respectively). The impact of lesion dynamics on survival, assessed by a joint model, varied greatly across organs, irrespective of treatment. Liver and locoregional lesion dynamics had a large impact on survival, with an increase of 10 mm of the lesion size increasing the instantaneous risk of death by 12% and 10%, respectively. In comparison, lymph nodes and lung lesions had a lower impact, with a 10-mm increase in the lesion size increasing the instantaneous risk of death by 7% and 5%, respectively. Using our model, we could anticipate the benefit of atezolizumab over chemotherapy as early as 6 months before the end of the study, which is 3 months earlier than a similar model only relying on SLD. Conclusion We showed the interest of organ-level tumor follow-up to better understand and anticipate the treatment effect on survival. Nine hundred metastatic urothelial carcinoma patients from the IMvigor211 phase III trial were treated with atezolizumab versus chemotherapy. A total of 4489 organ-specific measurements were made: 1544 measurements in the lymph, 999 in the lung, 691 in the liver, and 559 locoregionally. Longer treatment effect was observed in the lung (P value = 0.043) and liver (P = 0.001) lesions under atezolizumab compared to chemotherapy. Those with a 10-mm growth of liver lesion had their instantaneous risk of death increased by 12%, compared to 5% in the lung. Treatment effect on overall survival could be predicted based on early organ-specific tumor data 6 months after last patient inclusion.
Collapse
Affiliation(s)
- M Kerioui
- Université de Paris, INSERM IAME, Paris, France; Université de Tours, Université de Nantes, INSERM SPHERE, UMR 1246, Tours, France; Institut Roche, Boulogne-Billancourt, France; Clinical Pharmacology, Genentech/Roche, Paris, France.
| | - S Desmée
- Université de Tours, Université de Nantes, INSERM SPHERE, UMR 1246, Tours, France
| | - F Mercier
- F. Hoffmann-La Roche AG, Biostatistics, Basel, Switzerland
| | - A Lin
- Clinical Pharmacology, Genentech Inc., South San Francisco, USA
| | - B Wu
- Clinical Pharmacology, Genentech Inc., South San Francisco, USA
| | - J Y Jin
- Clinical Pharmacology, Genentech Inc., South San Francisco, USA
| | - X Shen
- Product Development, Genentech Inc., South San Francisco, USA
| | - C Le Tourneau
- Department of Drug Development and Innovation (D3i), INSERM U900 Research Unit, Paris-Saclay University, Paris & Saint-Cloud, France
| | - R Bruno
- Clinical Pharmacology, Genentech/Roche, Marseille, France
| | - J Guedj
- Université de Paris, INSERM IAME, Paris, France
| |
Collapse
|
10
|
Merli M, Rattotti S, Spina M, Re F, Motta M, Piazza F, Orsucci L, Ferreri AJ, Perbellini O, Dodero A, Vallisa D, Pulsoni A, Santoro A, Zuccaro V, Chimienti E, Russo F, Visco C, Zignego AL, Marcheselli L, Luminari S, Paulli M, Bruno R, Arcaini L. DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOCIATED INDOLENT NON‐HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE
FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2021. [DOI: 10.1002/hon.77_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Merli
- University Hospital "Ospedale di Circolo e Fondazione Macchi" ‐ ASST Sette Laghi University of Insubria Hematology Varese Italy
| | - S. Rattotti
- Fondazione IRCCS Policlinico San Matteo Hematology Pavia Italy
| | - M. Spina
- Centro di Riferimento Oncologico IRCCS Medical Oncology and Immune‐related Tumors Aviano (PN) Italy
| | - F. Re
- Azienda Ospedaliera Universitaria Hematology and BMT Center Parma Italy
| | - M. Motta
- ASST Spedali Civili Brescia Hematology Brescia Italy
| | - F. Piazza
- Azienda Ospedaliera‐Universitaria University of Padova Medicine, Hematology Padova Italy
| | - L. Orsucci
- Città della Salute e della Scienza di Torino Hematology Torino Italy
| | | | | | - A. Dodero
- Fondazione IRCCS Istituto Nazionale dei Tumori Hematology Milano Italy
| | - D. Vallisa
- Ospedale Guglielmo da Saliceto Hematology Piacenza Italy
| | - A. Pulsoni
- Sapienza University of Rome Translational and Precision Medicine Roma Italy
| | - A. Santoro
- Humanitas Research Hospital Medical Oncology and Hematology Unit Rozzano Milan Italy
| | - V. Zuccaro
- Fondazione IRCCS Policlinico San Matteo University of Pavia Infectious and Tropical Diseases Pavia Italy
| | - E. Chimienti
- Centro di Riferimento Oncologico IRCCS Medical Oncology and Immune‐related Tumors Aviano (PN) Italy
| | - F. Russo
- Azienda Ospedaliera Universitaria Hematology and BMT Center Parma Italy
| | - C. Visco
- University of Verona Medicine, Section of Hematology Verona Italy
| | - A. L. Zignego
- University of Florence Clinical and Experimental Medicine Interdepartmental Hepatology Center MASVE Florence Italy
| | | | - S. Luminari
- AUSL ‐ IRCCS Reggio Emilia University of Modena and Reggio Emilia Hematology Reggo Emilia Italy
| | - M. Paulli
- Fondazione IRCCS Policlinico San Matteo University of Pavia Anatomic Pathology Unit Pavia Italy
| | - R. Bruno
- Fondazione IRCCS Policlinico San Matteo University of Pavia Infectious and Tropical Diseases Pavia Italy
| | - L. Arcaini
- University of Pavia Molecular Medicine Pavia Italy
| |
Collapse
|
11
|
Botticella G, Pizzonia M, Cossu B, Bruno R, Camellino D, Girasole G, Giusti A, Pedrazzoni M, Alexovits S, Pleitavino F, Santolini F, Nencioni A, Bianchi G. POS1105 EFFECTS OF CHOLECALCIFEROL AND CALCIFEDIOL IN OSTEOPOROTIC WOMEN WITH SECONDARY HYPERPARATHYROIDISM DUE TO SEVERE VITAMIN D DEFICIENCY UNDERGOING ZOLEDRONIC ACID TREATMENT: A RANDOMIZED-CONTROLLED TRIAL. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Secondary hyperparathyroidism (sHPTH) due to vitamin D deficiency impairs the bone mineral density (BMD) response to alendronate,1-2 but the optimal strategy for its correction in postmenopausal osteoporotic women (PMO) about to start zoledronic acid (ZOL) therapy is still unknown.Objectives:To evaluate the effects of cholecalciferol (D3) and calcifediol (25OHD) on serum 25-OH-vitamin D (s25OHD), parathyroid hormone (PTH) and BMD in PMO presenting with sHPTH due to vitamin D deficiency.Methods:PMO with s25OHD <20 ng/ml, sHPTH (PTH >65 pg/ml) and BMD T-score at the lumbar spine (LS), femoral neck (FN) or total hip (TH) < -2.5, or between -1 and -2.5 plus one vertebral/femoral fracture, were randomly assigned to receive a therapeutic dose of D3 (300.000 IU bolus) followed by 175 mcg/weekly of D3, or 175 mcg/weekly of 25OHD alone, 2 months before receiving a single intravenous infusion of ZOL (5 mg). BMD at the LS, FN and TH was assessed at baseline and after one year from ZOL. Serum calcium, PTH and s25OHD were measured at baseline, and 6- and 12-month after ZOL. Adverse and clinical events were ascertained by 3-and 9-month telephone interviews, and by 6- and 12-month clinical evaluation.Results:45 PMO (25OHD N=23, D3 N=22) were enrolled over one year and 32 subjects (mean age ±SD 75±10 years, range 51-91) completed the 1-year of treatment/follow-up (25OHD N=17, D3 N=15). Most PMO discontinued for protocol violation, while three deceased before study ending (25OHD N=1, D3 N=2) for reasons not related to the agents investigated. The baseline characteristics were comparable in both groups. At baseline mean s25OHD (±SE) was 8±1 ng/ml in the 25OHD group and 8±1 ng/ml in the D3 group. The corresponding figures for PTH were 111±6 pg/ml (25OHD) and 117±5 pg/ml (D3). Mean s25OHD (±SE) increased in both groups at 6- and 12-month, being significantly greater in the 25OHD group (12-month, 56±2 ng/ml) compared to the D3 group (12-month, 34±2 ng/ml, P<.001) at both time points (Figure 1). PTH (mean ±SE) decreased in both groups, being significantly lower in the 25OHD group at 12-month (25OHD 46±6 pg/ml versus D3 70±6 pg/ml, P=.007), as shown in Figure 1. BMD at the LS, FN and TH increased in both groups (with significant increases versus baseline only at the FN) without significant differences between s25OHD and D3. In PMO receiving D3 serum calcium remained stable over time, while those receiving s25OHD demonstrated a significant increase of serum calcium, with 2 PMO presenting a value close to the upper limit of the reference range at 12-month. No patient reported incident fractures or adverse events.Conclusion:Calcifediol 175 mcg weekly appears more potent in improving s25OHD and decreasing PTH concentrations compared to cholecalciferol therapeutic dose (300’000 IU) plus 175 mcg weekly in PMO presenting with sHPTH due to severe vitamin D deficiency about to start ZOL therapy. Further studies are warranted to clarify implications on BMD improvements on the long-term of similar 25OHD and D3 regimens.References:[1]Barone A et al., J Am Geriatr Soc 2007.[2]Kincse G et al., BMC Musculoskelet Disord 2012.Disclosure of Interests:Giulia Botticella: None declared, Monica Pizzonia: None declared, Barbara Cossu: None declared, Roberta Bruno: None declared, Dario Camellino Speakers bureau: AbbVie, Celgene, Janssen-Cilag, Eli Lilly, Medac, Mylan, Novartis, and Sanofi, outside the submitted work, Giuseppe Girasole Speakers bureau: Abiogen Pharma and Novartis, outside the submitted work, Andrea Giusti Speakers bureau: UCB, Amgen, Kyowa Kirin, Abiogen Pharma, and Eli Lilly, outside the submitted work, Consultant of: EffRx and Abiogen Pharma, outside the submitted work, Mario Pedrazzoni: None declared, Simona Alexovits: None declared, Franco Pleitavino: None declared, Federico Santolini: None declared, Alessio Nencioni: None declared, Gerolamo Bianchi Speakers bureau: Abbvie, Abiogen Pharma, Amgen, BMS, Celgene, Eli Lilly, GSK, Janssen-Cilag, Medac, MSD, Novartis, Pfizer, Roche, Sanofi, Genzyme, and Servier, outside the submitted work.
Collapse
|
12
|
Immohr M, Aubin H, Westenfeld R, Mehdiani A, Scheiber D, Bruno R, Tudorache I, Akhyari P, Lichtenberg A, Boeken U. Treatment of Donor-Specific Antibody Mediated Rejection after Heart Transplantation by IGM-Enriched Human Intravenous Immunoglobulin. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
13
|
Gazia F, Galletti B, Freni F, Bruno R, Sireci F, Galletti C, Meduri A, Galletti F. Use of intralesional cidofovir in the recurrent respiratory papillomatosis: a review of the literature. Eur Rev Med Pharmacol Sci 2021; 24:956-962. [PMID: 32017003 DOI: 10.26355/eurrev_202001_20081] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Recurrent respiratory papillomatosis (RRP) is characterized by exophytic, benign, and papillary lesions infected by the virus in the epithelium of the upper aerodigestive tract. RRP is caused by persistent infection of the respiratory epithelium by human papillomavirus (HPV) HPV6 and-11. The clinical course of RRP is unpredictable, frequently relapsing, and may be lifelong. The aim of this study is to evaluate the efficacy and safety of the use of intralesional Cidofovir in the treatment of RRP. PATIENTS AND METHODS We have selected articles on the use of cidofovir as adjuvant therapy in laryngeal papillomatosis. We reviewed 20 reports that enrolled 185 patients with "adult onset recurrent respiratory papillomatosis" (AORRP) and 85 patients with "juvenile onset recurrent respiratory papillomatosis" (JORRP). We evaluated concentration of cidofovir, number of injections, injection interval, therapeutic response, side effects, and progression to dysplasia. RESULTS The mean concentration of cidofovir was 7.5 mg/ml at injection. The mean number of injections per patient is 6 with 26 days between injections. The percentage of patients with dysplasia after use of cidofovir is 1.48%. The AORRP response to cidofovir is better with a 74% complete response rate, compared to 56.5% of the JORRP. CONCLUSIONS Intralesion use of cidofovir has a good adjuvant action in RRP increasing the complete remission of the disease. The treatment does not increase the risk of laryngeal dysplasia.
Collapse
Affiliation(s)
- F Gazia
- Department of Adult and Development Age Human Pathology "Gaetano Barresi", Unit of Otorhinolaryngology, University of Messina, Messina, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Percivalle E, Clerici M, Cassaniti I, Vecchio Nepita E, Marchese P, Olivati D, Catelli C, Berri A, Baldanti F, Marone P, Bruno R, Triarico A, Lago P. SARS-CoV-2 viability on different surfaces after gaseous ozone treatment: a preliminary evaluation. J Hosp Infect 2021; 110:33-36. [PMID: 33516798 PMCID: PMC7842195 DOI: 10.1016/j.jhin.2021.01.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Revised: 01/19/2021] [Accepted: 01/20/2021] [Indexed: 12/13/2022]
Abstract
COVID-19 is a global health threat with a huge number of confirmed cases and deaths all over the world. Human-to-human transmission via respiratory droplets and contact with aerosol-infected surfaces are the major routes of virus spread. Because SARS-CoV-2 can remain in the air and on surfaces from several hours to several days, disinfection of frequently touched surfaces and critical rooms, in addition to observing individual hygiene tips, is required to reduce the virus spreading. Here we report on an investigation into the use of gaseous ozone as a potentially effective sanitizing method against the new coronavirus.
Collapse
Affiliation(s)
- E Percivalle
- Molecular Virology Unit, Microbiology and Virology Department, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy
| | - M Clerici
- P.C. di Pompeo Catelli SRL, Uggiate Trevano, Como, Italy.
| | - I Cassaniti
- Molecular Virology Unit, Microbiology and Virology Department, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy
| | - E Vecchio Nepita
- Molecular Virology Unit, Microbiology and Virology Department, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy
| | - P Marchese
- Safety Bio Life SRL, Albuzzano, Pavia, Italy
| | - D Olivati
- Safety Bio Life SRL, Albuzzano, Pavia, Italy
| | - C Catelli
- P.C. di Pompeo Catelli SRL, Uggiate Trevano, Como, Italy
| | - A Berri
- Safety Bio Life SRL, Albuzzano, Pavia, Italy
| | - F Baldanti
- Molecular Virology Unit, Microbiology and Virology Department, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy
| | - P Marone
- Molecular Virology Unit, Microbiology and Virology Department, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy
| | - R Bruno
- Infection Diseases Department, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy
| | - A Triarico
- Medical Direction, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy
| | - P Lago
- Clinical Engineering Department, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, ITALY; Industrial and Information Engineering Department, University of Pavia, Pavia, ITALY
| |
Collapse
|
15
|
Immohr MB, Aubin H, Westenfeld R, Bruno R, Dalyanolgu H, Erbel-Khurtsidze S, Tudorache I, Akhyari P, Lichtenberg A, Boeken U. Heart Transplantation in an Aging Society: Impact of Recipient Age on Postoperative Outcome. Thorac Cardiovasc Surg 2021. [DOI: 10.1055/s-0041-1725802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
16
|
Immohr MB, Aubin H, Westenfeld R, Mehdiani A, Scheiber D, Bruno R, Tudorache I, Akhyari P, Lichtenberg A, Boeken U. Treatment of Donor-Specific Antibody-Mediated Rejection After Heart Transplantation by IGM-Enriched Human Intravenous Immunoglobulin. Thorac Cardiovasc Surg 2021. [DOI: 10.1055/s-0041-1725614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
17
|
Rovida F, Cereda D, Novati S, Licari A, Triarico A, Marseglia GL, Bruno R, Baldanti F. Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy. Clin Microbiol Infect 2020; 26:1569-1571. [PMID: 32535148 PMCID: PMC7289743 DOI: 10.1016/j.cmi.2020.06.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 05/28/2020] [Accepted: 06/06/2020] [Indexed: 01/08/2023]
Affiliation(s)
- F Rovida
- UOS Virologia Molecolare, UOC Microbiologia e Virologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - D Cereda
- DG Welfare, UO Prevenzione, Lombardy Region, Milan, Italy
| | - S Novati
- Clinica di Malattie Infettive, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - A Licari
- Department of Paediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
| | - A Triarico
- Direzione Sanitaria, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - G L Marseglia
- Department of Paediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
| | - R Bruno
- Clinica di Malattie Infettive, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - F Baldanti
- UOS Virologia Molecolare, UOC Microbiologia e Virologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy.
| | | |
Collapse
|
18
|
Tassorelli C, Mojoli F, Baldanti F, Bruno R, Benazzo M. COVID-19: what if the brain had a role in causing the deaths? Eur J Neurol 2020; 27:e41-e42. [PMID: 32333819 PMCID: PMC7267268 DOI: 10.1111/ene.14275] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Accepted: 04/18/2020] [Indexed: 12/19/2022]
Affiliation(s)
- C Tassorelli
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.,IRCCS Mondino Foundation, Pavia, Italy
| | - F Mojoli
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.,Department of Anaesthesia and Intensive Care, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - F Baldanti
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.,Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - R Bruno
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.,Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - M Benazzo
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.,Department of Otorhinolaryngology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| |
Collapse
|
19
|
Asperges E, Novati S, Muzzi A, Biscarini S, Sciarra M, Lupi M, Sambo M, Gallazzi I, Peverini M, Lago P, Mojoli F, Perlini S, Bruno R. Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre. J Hosp Infect 2020; 105:S0195-6701(20)30119-5. [PMID: 32205162 PMCID: PMC7118420 DOI: 10.1016/j.jhin.2020.03.020] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Accepted: 03/16/2020] [Indexed: 11/21/2022]
Affiliation(s)
- E Asperges
- Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - S Novati
- Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - A Muzzi
- Direzione Medica and Risk Management, Fondazione IRCCS Policlinico San Matteo, Pavia
| | - S Biscarini
- Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - M Sciarra
- Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - M Lupi
- Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - M Sambo
- Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - I Gallazzi
- Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - M Peverini
- Department of Architecture and Urban Studies, Politecnico di Milano, Milano, Italy
| | - P Lago
- Clinical Engineering, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - F Mojoli
- Anesthesia and Intensive Care, Emergency Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Clinical, Surgical, Diagnostic, and Paediatric Sciences, University of Pavia, Pavia, Italy
| | - S Perlini
- Emergency Department, Fondazione IRCCS Policlinico San Matteo, and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
| | - R Bruno
- Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Clinical, Surgical, Diagnostic, and Paediatric Sciences, University of Pavia, Pavia, Italy.
| |
Collapse
|
20
|
Prediletto I, Vasile E, Bruno R, Macerola E, Pasquini G, Fontanini G, Falcone A. Pre-treatment EGFR-T790M subclones in lung adenocarcinoma harboring activating mutation of EGFR: A positive prognostic factor for survival? Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Lovell ME, Bruno R, Johnston J, Matthews A, McGregor I, Allsop DJ, Lintzeris N. Cognitive, physical, and mental health outcomes between long-term cannabis and tobacco users. Addict Behav 2018; 79:178-188. [PMID: 29291509 DOI: 10.1016/j.addbeh.2017.12.009] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Revised: 11/17/2017] [Accepted: 12/07/2017] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Cannabis intoxication adversely affects health, yet persistent effects following short-term abstinence in long-term cannabis users are unclear. This matched-subjects, cross-sectional study compared health outcomes of long-term cannabis and long-term tobacco-only users, relative to population norms. METHODS Nineteen long-term (mean 32.3years of use, mean age 55.7years), abstinent (mean 15h) cannabis users and 16 long-term tobacco users (mean 37.1years of use, mean age 52.9years), matched for age, educational attainment, and lifetime tobacco consumption, were compared on measures of learning and memory, response inhibition, information-processing, sustained attention, executive control, and mental and physical health. RESULTS Cannabis users exhibited poorer overall learning and delayed recall and greater interference and forgetting than tobacco users, and exhibited poorer recall than norms. Inhibition and executive control were similar between groups, but cannabis users had slower reaction times during information processing and sustained attention tasks. Cannabis users had superior health satisfaction and psychological, somatic, and general health than tobacco users and had similar mental and physical health to norms whilst tobacco users had greater stress, role limitations from emotional problems, and poorer health satisfaction. CONCLUSIONS Long-term cannabis users may exhibit deficits in some cognitive domains despite short-term abstinence and may therefore benefit from interventions to improve cognitive performance. Tobacco alone may contribute to adverse mental and physical health outcomes, which requires appropriate control in future studies.
Collapse
Affiliation(s)
- M E Lovell
- School of Medicine (Psychology), University of Tasmania, Hobart, Tasmania 7000, Australia.
| | - R Bruno
- School of Medicine (Psychology), University of Tasmania, Hobart, Tasmania 7000, Australia
| | - J Johnston
- University Centre for Rural Health - North Coast, University of Sydney, Lismore, New South Wales 2480, Australia
| | - A Matthews
- School of Medicine (Psychology), University of Tasmania, Hobart, Tasmania 7000, Australia
| | - I McGregor
- Lambert Initiative for Cannabinoid Therapeutics, School of Psychology, Brain and Mind Centre, University of Sydney, New South Wales 2006, Australia
| | - D J Allsop
- Lambert Initiative for Cannabinoid Therapeutics, School of Psychology, Brain and Mind Centre, University of Sydney, New South Wales 2006, Australia
| | - N Lintzeris
- Discipline of Addictive Medicine, Sydney Medical School, University of Sydney, Sydney, New South Wales 2006, Australia; The Langton Centre, South East Sydney Local Health District (SESLHD), Drug and Alcohol Services, 2010, Australia
| |
Collapse
|
22
|
Donnarumma L, Bruno R, Terlizzi A, Russo GF. Population ecology of Jujubinus striatus and Jujubinus exasperatus (Gastropoda: Trochidae) in a Posidonia oceanica seagrass bed. The European Zoological Journal 2018. [DOI: 10.1080/24750263.2017.1420828] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- L. Donnarumma
- Dipartimento di Scienze e Tecnologie, Università di Napoli “Parthenope”, CoNISMa, Napoli, Italy
| | - R. Bruno
- Dipartimento di Scienze e Tecnologie, Università di Napoli “Parthenope”, CoNISMa, Napoli, Italy
| | - A. Terlizzi
- Dipartimento di Scienze della Vita, Università degli Studi di Trieste, CoNISMa, Trieste, Italy
- Stazione Zoologica A. Dohrn, Napoli, Italy
| | - G. F. Russo
- Dipartimento di Scienze e Tecnologie, Università di Napoli “Parthenope”, CoNISMa, Napoli, Italy
| |
Collapse
|
23
|
Abstract
Risky paternal alcohol use is associated with maternal alcohol use during pregnancy, poor fetal and infant outcomes, domestic violence and depression. This study developed 30 SMS text messages about alcohol for fathers who drink at risky levels. The text messages were developed using two motivational styles: messages presented in a second person voice and the same messages presented in a child's voice. Fifty-one fathers were recruited through social media to complete an online survey rating the SMS text messages for message importance and likelihood of seeking further information and measuring risky alcohol use and psychosocial distress. Seventeen participants then participated in a semi-structured qualitative interview. Fathers rated the text messages presented in the child's voice as more important than messages presented in the second person. Qualitative data supported survey results that motivational SMS text messages could provide an acceptable way to raise awareness of risky alcohol consumption for future fathers.
Collapse
Affiliation(s)
- Maryanne Robinson
- School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales Australia
- 12 Alfred Street, Newcastle East, New South Wales 2300 Australia
| | - R. B. Wilkinson
- School of Psychology, Faculty of Science, University of Newcastle, Callaghan, New South Wales Australia
| | - R. Fletcher
- Family Action Centre, School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales Australia
| | - R. Bruno
- School of Medicine, University of Tasmania, Hobart, Australia
| | - A. L. Baker
- School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales Australia
| | - L. Maher
- The Kirby Institute, University of New South Wales, Sydney, New South Wales Australia
| | - J. Wroe
- Family Action Centre, School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales Australia
| | - A. J. Dunlop
- School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales Australia
- Drug and Alcohol Clinical Services, Hunter New England Local Health District, New Lambton, New South Wales Australia
- Centre for Brain and Mental Health, University of Newcastle, Callaghan, New South Wales Australia
- Hunter Medical Research Institute, New Lambton Heights, New South Wales Australia
| |
Collapse
|
24
|
Landi L, Chiari R, Dazzi C, Tiseo M, Chella A, Delmonte A, Bonanno L, Cortinovis D, De Marinis F, Minuti G, Buosi R, Morabito A, Spitaleri G, Gridelli C, Maione P, Galetta D, Barbieri F, Grossi F, Novello S, Bruno R, Alì G, Proietti A, Fontanini G, Joseph A, Crinò L, Cappuzzo F. P1.01-015 Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Final Results of the METROS Trial. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Landi L, Chiari R, Dazzi C, Tiseo M, Chella A, Delmonte A, Bonanno L, Cortinovis D, de Marinis F, Minuti G, Buosi R, Morabito A, Maione P, Galetta D, Barbieri F, Grossi F, Novello S, Bruno R, Fontanini G, Crinò L, Cappuzzo F. Crizotinib in ROS1 rearranged or MET deregulated non-small-cell lung cancer (NSCLC): final results of the METROS trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Bruno R, Di Pilla M, Buralli S, Sgrò M, Modesti P, Taddei S, Ghiadoni L. [PP.19.24] DETERMINANTS OF INAPPROPRIATELY HIGH PULSE WAVE VELOCITY IN HYPERTENSIVE PATIENTS. J Hypertens 2017. [DOI: 10.1097/01.hjh.0000523714.41136.ad] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, Gaeta GB, Galli M, Girmenia C, Mikulska M, Pane F, Perno CF, Picardi M, Puoti M, Rambaldi A, Svicher V, Taliani G, Gentile G. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect 2017; 23:935-940. [PMID: 28668466 DOI: 10.1016/j.cmi.2017.06.023] [Citation(s) in RCA: 60] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2017] [Revised: 06/15/2017] [Accepted: 06/17/2017] [Indexed: 12/18/2022]
Abstract
SCOPE Hepatitis B virus (HBV) infection reactivation is associated with high morbidity and mortality in patients with haematologic malignancy and/or haematopoietic stem cell transplantation (HSCT). However, information on this issue is limited. The scope of this position paper is to provide recommendations on HBV screening, monitoring, prophylaxis, treatment and vaccination in the patients described above. METHODS These recommendations were developed from one meeting of experts attended by different Italian scientific societies as well as from a systematic literature review (of articles published through December 31, 2016) on HBV infection in haematologic patients and in patients who underwent haematopoietic stem cell transplantation published in the same issue of the journal. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess each recommendation's quality. QUESTIONS ADDRESSED These recommendations provide the answers to the following questions: (a) HBV screening and monitoring: Who should be screened before chemotherapy? Which screening tests should be used? Should HBV-DNA detection be used to monitor HBV reactivation before starting antivirals? What is the best timeline to monitor HBV reactivation? (b) Prophylaxis in HBsAg-positive patients: Which antiviral drugs should be used to treat HBsAg-positive patients? How long should antiviral prophylaxis be provided to HBsAg-positive patients? (c) Prophylaxis in patients with resolved HBV infection: Which patients with resolved HBV infection should receive antiviral prophylaxis? Which antiviral drug should be used? How long should antiviral prophylaxis be provided? (d) HBV infection management strategy in autologous (auto-HSCT) and allogeneic HSCT (allo-HSCT): Which HSCT recipients should receive antiviral prophylaxis? Which antiviral drug should be used? How long should antiviral prophylaxis be provided? (e) Choice of antiviral drugs in the treatment of HBV reactivation: Should third-generation anti-HBV drugs be preferred to first- or second-generation antiviral drugs in the treatment of HBV reactivation with or without hepatitis flare in haematologic patients? (f) Immunization against HBV in patients with haematologic malignancies and/or patients who underwent HSCT: Should these patients be vaccinated? Which HBV vaccination schedule should be adopted? RECOMMENDATIONS Haematologic patients should be screened for hepatitis B surface antigen (HBsAg) plus anti-hepatitis B core protein (HBc), and HBV DNA before chemotherapy. HBV DNA levels should be monitored monthly in all HBV-positive patients who do not receive prophylaxis. HBsAg-positive haematologic patients and those undergoing HSCT should receive third-generation antiviral therapy as prophylaxis. Anti-HBc-positive lymphoma patients and those receiving HSCT should receive antiviral prophylaxis. All HBV-negative haematologic patients should be vaccinated for HBV. The acquisition of data from well-designed studies is desirable in the near future.
Collapse
Affiliation(s)
- L Sarmati
- Department of System Medicine, Clinical Infectious Diseases, Tor Vergata University, Rome, Italy.
| | - M Andreoni
- Department of System Medicine, Clinical Infectious Diseases, Tor Vergata University, Rome, Italy
| | - G Antonelli
- Department of Molecular Medicine, 'La Sapienza' University, Rome, Italy
| | - W Arcese
- Department of Hematology, Stem Cell Transplant Unit, Tor Vergata University, Rome, Italy
| | - R Bruno
- Department of Infectious Diseases, Hepatology Outpatients Unit, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
| | - N Coppola
- Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy
| | - G B Gaeta
- Infectious Diseases and Viral Hepatitis, Department of Mental and Physical Health and Preventive Medicine, Università della Campania, Naples, Italy
| | - M Galli
- Infectious Diseases Unit, University of Milan, L. Sacco Hospital, Milan, Italy
| | - C Girmenia
- Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa, Azienda Policlinico Umberto I, La Sapienza University, Rome, Italy
| | - M Mikulska
- Division of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy; Division of Infectious Diseases, IRCCS San Martino University Hospital-IST, Genoa, Italy
| | - F Pane
- Department of Clinical Medicine and Surgery, Hematology, Federico II University, Naples, Italy
| | - C F Perno
- Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy
| | - M Picardi
- Department of Clinical Medicine and Surgery, Hematology, Federico II University, Naples, Italy
| | - M Puoti
- Infectious Diseases Department, Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan, Italy
| | - A Rambaldi
- Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Milan, Italy; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | - V Svicher
- Department of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy
| | - G Taliani
- Clinic of Infectious and Tropical Medicine, Policlinico Umberto I, Rome, Italy
| | - G Gentile
- Department of Cellular Biotechnologies and Hematology, 'La Sapienza' University, Rome, Italy
| |
Collapse
|
28
|
Jacka B, Peacock A, Degenhardt L, Bruno R, Clare P, Kemp R, Dev A, Larance B. Trends in PIEDs use among male clients of needle-syringe programs in Queensland, Australia; 2007-2015. Int J Drug Policy 2017. [PMID: 28651113 DOI: 10.1016/j.drugpo.2017.05.048] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- B Jacka
- National Drug and Alcohol Research Centre, UNSW, Sydney, NSW, Australia; Kirby Institute, UNSW, Sydney, NSW, Australia
| | - A Peacock
- National Drug and Alcohol Research Centre, UNSW, Sydney, NSW, Australia; School of Medicine (Psychology), University of Tasmania, Tasmania Australia
| | - L Degenhardt
- National Drug and Alcohol Research Centre, UNSW, Sydney, NSW, Australia
| | - R Bruno
- School of Medicine (Psychology), University of Tasmania, Tasmania Australia
| | - P Clare
- National Drug and Alcohol Research Centre, UNSW, Sydney, NSW, Australia
| | - R Kemp
- Communicable Diseases Branch, Queensland Health, QLD, Australia
| | - A Dev
- Chief Medical Officer and Healthcare Regulation Branch, Queensland Health, QLD Australia
| | - B Larance
- National Drug and Alcohol Research Centre, UNSW, Sydney, NSW, Australia.
| |
Collapse
|
29
|
Stroh M, Winter H, Marchand M, Claret L, Eppler S, Ruppel J, Abidoye O, Teng SL, Lin WT, Dayog S, Bruno R, Jin J, Girish S. Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma. Clin Pharmacol Ther 2017; 102:305-312. [PMID: 27981577 DOI: 10.1002/cpt.587] [Citation(s) in RCA: 98] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2016] [Revised: 10/18/2016] [Accepted: 11/18/2016] [Indexed: 12/14/2022]
Abstract
Atezolizumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting human programmed death-ligand 1 (PD-L1), is US Food and Drug Administration (FDA) approved in metastatic urothelial carcinoma (MUC) and is being investigated in various malignancies. This analysis based upon 906 patients from two phase I and one phase II MUC studies, is the first report of the clinical pharmacokinetics (PK) and pharmacodynamics (PD) of atezolizumab. Atezolizumab exhibited linear PK over a dose range of 1-20 mg/kg, including the labeled 1,200 mg dose. The clearance, volume of distribution, and terminal half-life estimates from population pharmacokinetic (PopPK) analysis of 0.200 L/day, 6.91 L, and 27 days, respectively, were as expected for an IgG1. Exposure-response analyses did not identify statistically significant relationships with either objective response rate or adverse events of grades 3-5 or of special interest. None of the statistically significant covariates from PopPK (body weight, gender, antitherapeutic antibody, albumin, and tumor burden) would require dose adjustment.
Collapse
Affiliation(s)
- M Stroh
- Genentech, South San Francisco, California, USA
| | - H Winter
- Genentech, South San Francisco, California, USA
| | - M Marchand
- Pharsight Consulting Services, Marseille, France
| | - L Claret
- Pharsight Consulting Services, Marseille, France
| | - S Eppler
- Genentech, South San Francisco, California, USA
| | - J Ruppel
- Genentech, South San Francisco, California, USA
| | - O Abidoye
- Genentech, South San Francisco, California, USA
| | - S L Teng
- Genentech, South San Francisco, California, USA
| | - W T Lin
- Genentech, South San Francisco, California, USA
| | - S Dayog
- Genentech, South San Francisco, California, USA
| | - R Bruno
- Pharsight Consulting Services, Marseille, France
| | - J Jin
- Genentech, South San Francisco, California, USA
| | - S Girish
- Genentech, South San Francisco, California, USA
| |
Collapse
|
30
|
Affiliation(s)
- A Carbone
- Endocrine Unit, Tinchi Hospital, Matera, Italy
| | - G Lagonigro
- Endocrine Unit, Tinchi Hospital, Matera, Italy
| | - R Bruno
- Endocrine Unit, Tinchi Hospital, Matera, Italy.
| |
Collapse
|
31
|
Frigeni M, Visco C, Besson C, Rattotti S, Fontaine H, Goldaniga M, Visentini M, Torres H, Peveling-Oberhag J, Rossotti R, Zaja F, Rigacci L, Merli M, Dorival C, Alric L, Piazza F, Gentile M, Ferrari A, Pirisi M, Tedeschi A, Defrancesco I, Ferretti V, Bruno R, Hermine O, Arcaini L. INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Frigeni
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - C. Visco
- Department of Cell Therapy and Hematology; San Bortolo Hospital; Vicenza Italy
| | - C. Besson
- Université Paris Sud, INSERM; Assistance Publique-Hôpitaux de Paris Centre Hospitalier Universitaire Bicêtre; Le Kremlin-Bicêtre France
| | - S. Rattotti
- Department of Hematology Oncology; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| | - H. Fontaine
- Paris 5 Descartes University; INSERM U1213 and Unité Mixte de Service 20; Institut Pasteur, Department of Hepatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; Paris France
| | - M. Goldaniga
- Department of Hematology, Fondazione Ospedale Maggiore Policlinico; Mangiagalli e Regina Elena; Milan Italy
| | - M. Visentini
- Division of Clinical Immunology; Sapienza University of Rome, Fondazione Roma; Rome Italy
| | - H.A. Torres
- Department of Infectious Diseases, Infection Control, and Employee Health; The University of Texas MD Anderson Cancer Center; Houston Texas USA
| | - J. Peveling-Oberhag
- Department of Internal Medicine 1; Goethe-University Hospital; Frankfurt Germany
| | - R. Rossotti
- Department of Infectious Diseases; Ospedale Niguarda Ca’ Granda; Milan Italy
| | - F. Zaja
- Hematology Unit, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Sanitaria Universitaria Integrata; Udine Italy
| | - L. Rigacci
- Department of Hematology; Azienda Ospedaliero-Universitaria Careggi; Florence Italy
| | - M. Merli
- Division of Hematology, Ospedale di Circolo e Fondazione Macchi; University of Insubria; Varese Italy
| | - C. Dorival
- Sorbonne Universités, Pierre and Marie Curie University (University of Paris 06), INSERM; Institut Pierre Louis d'épidémiologie et de Santé Publique (Unité mixte de recherche S1136); Paris France
| | - L. Alric
- Toulouse 3 University, Unité mixte de recherche 152 Institut de Recherche pour le Développement; Department of Internal Medicine and Digestive Diseases, Hôpital Purpan; Toulouse France
| | - F. Piazza
- Hematology and Clinical Immunology Unit, Department of Medicine; University of Padua; Padua Italy
| | - M. Gentile
- Hematology Unit; Azienda Ospedaliera di Cosenza; Cosenza Italy
| | - A. Ferrari
- Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico; Reggio Emilia Italy
| | - M. Pirisi
- Department of Translational Medicine; Università degli Studi del Piemonte Orientale "A. Avogadro"; Novara Italy
| | - A. Tedeschi
- Department of Hematology, Niguarda Cancer Center, Ospedale Niguarda Ca’ Granda; Milan Italy
| | - I. Defrancesco
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - V.V. Ferretti
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - R. Bruno
- Division of Infectious and Tropical Diseases, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| | - O. Hermine
- Paris 5 Descartes University; AP-HP, Department of Adult Hematology and Imagine Institute, Hôpital Necker; Paris France
| | - L. Arcaini
- Department of Hematology Oncology; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| |
Collapse
|
32
|
Merli M, Alric L, Mannelli L, De Angelis F, Ferrari A, Capecchi M, Pirisi M, Visco C, Piazza F, Loustaud-Ratti V, Goldaniga M, Zancanella M, Cencini E, Marino D, Benanti F, Rumi M, Frigeni M, Gotti M, Sciarra R, Ferretti V, Grossi P, Passamonti F, Bruno R, Arcaini L. DIRECT-ACTING ANTIVIRALS DURING OR AFTER IMMUNO-CHEMOTHERAPY IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Merli
- Hematology; University Hospital Ospedale di Circolo e Fondazione Macchi-ASST Sette Laghi, University of Insubria; Varese Italy
| | - L. Alric
- Internal Medicine and Digestive Diseases; Toulouse 3 University, Unité mixte de recherche 152, Institut de recherche 152, Institut de Récherche pour le Developpement, Hopital Purpan; Toulouse France
| | - L. Mannelli
- Hematology; Azienda Ospedaliera Careggi; Florence Italy
| | - F. De Angelis
- Cellular Biotechnologies and Hematology; Sapienza University of Rome; Rome Italy
| | - A. Ferrari
- Hematology; IRCCS Arcispedale Santa Maria Nuova; Reggio Emilia Italy
| | - M. Capecchi
- Hematology; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - M. Pirisi
- Translational Medicine; University of Piemonte Orientale UPO; Novara Italy
| | - C. Visco
- Cell Therapy and Hematology; Ospedale San Bortolo; Vicenza Italy
| | - F. Piazza
- Medicine-Hematology; University of Padova; Padova Italy
| | - V. Loustaud-Ratti
- Hepatology; Centre Hospitalier Universitaire Limoges, U850 INSERM, Université de Limoges; Limoges France
| | - M. Goldaniga
- Hematology; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milan Italy
| | - M. Zancanella
- Hematology and Oncology, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda; Milan Italy
| | - E. Cencini
- Hematology, Azienda Ospedaliera Senese; University of Siena; Siena Italy
| | - D. Marino
- Oncology Unit 1, Veneto Institute of Oncology IOV_IRCCS; Padova Italy
| | - F. Benanti
- Infectious Diseases; University of Catania; Catania Italy
| | - M. Rumi
- Hepatology, Ospedale San Giuseppe IRCCS Multimedica; University of Milan; Milan Italy
| | - M. Frigeni
- Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - M. Gotti
- Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - R. Sciarra
- Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - V. Ferretti
- Molecular Medicine; University of Pavia; Pavia Italy
| | - P. Grossi
- Infectious and Tropical Diseases; University Hospital Ospedale di Circolo e Fondazione Macchi -ASST Sette Laghi, University of Insubria; Varese Italy
| | - F. Passamonti
- Hematology; University Hospital Ospedale di Circolo e Fondazione Macchi-ASST Sette Laghi, University of Insubria; Varese Italy
| | - R. Bruno
- Infectious and Tropical Diseases, Fondazione IRCCS Policlinico San Matteo; University of Pavia; Pavia Italy
| | - L. Arcaini
- Molecular Medicine; University of Pavia; Pavia Italy
| |
Collapse
|
33
|
Claret L, Han K, Bruno R. Model-Based Estimates of Tumor Growth Inhibition Metrics Are Time-Independent: A Reply to Mistry. CPT Pharmacometrics Syst Pharmacol 2017; 6:225. [PMID: 27997740 PMCID: PMC5397555 DOI: 10.1002/psp4.12163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2016] [Accepted: 12/06/2016] [Indexed: 11/15/2022] Open
Affiliation(s)
- L Claret
- Clinical Pharmacology; Genentech/Roche; Marseille France
| | - K Han
- Clinical Pharmacology Modeling & Simulations; GlaxoSmithKline; Philadelphia Pennsylvania USA
| | - R Bruno
- Clinical Pharmacology; Genentech/Roche; Marseille France
| |
Collapse
|
34
|
Mariani M, Zuccaro V, Patruno SFA, Scudeller L, Sacchi P, Lombardi A, Vecchia M, Columpsi P, Marone P, Filice G, Bruno R. The impact of rifaximin in the prevention of bacterial infections in cirrhosis. Eur Rev Med Pharmacol Sci 2017; 21:1151-1158. [PMID: 28338174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
OBJECTIVE Bacterial infections are a leading factor in the progression from compensated to decompensated cirrhosis, with consequent worsening of the prognosis, and concerted efforts have been made to reduce infections and improve the survival rate of these patients. We retrospectively investigated the rate of infections in hospitalized cirrhotic patients under treatment with rifaximin. PATIENTS AND METHODS We enrolled 649 patients whose clinical and personal data, prescribed therapy, microbiological findings and laboratory tests were collected from previous discharge letters and our institution database. The efficacy of rifaximin in preventing several types infection was evaluated by comparing outcomes for rifaximin-treated patients vs patients receiving no antibiotic treatment. RESULTS The risk of developing selected bacterial infections was significantly lower in patients treated with rifaximin (OR 0.29; 95% CI 0.20-0.40, p < 0.001). CONCLUSIONS Continuous treatment with rifaximin may prevent bacterial infections in cirrhotic patients.
Collapse
Affiliation(s)
- M Mariani
- Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Mattick RP, Wadolowski M, Aiken A, Clare PJ, Hutchinson D, Najman J, Slade T, Bruno R, McBride N, Degenhardt L, Kypri K. Parental supply of alcohol and alcohol consumption in adolescence: prospective cohort study. Psychol Med 2017; 47:267-278. [PMID: 27702422 DOI: 10.1017/s0033291716002373] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Parents are a major supplier of alcohol to adolescents, yet there is limited research examining the impact of this on adolescent alcohol use. This study investigates associations between parental supply of alcohol, supply from other sources, and adolescent drinking, adjusting for child, parent, family and peer variables. METHOD A cohort of 1927 adolescents was surveyed annually from 2010 to 2014. Measures include: consumption of whole drinks; binge drinking (>4 standard drinks on any occasion); parental supply of alcohol; supply from other sources; child, parent, family and peer covariates. RESULTS After adjustment, adolescents supplied alcohol by parents had higher odds of drinking whole beverages [odds ratio (OR) 1.80, 95% confidence interval (CI) 1.33-2.45] than those not supplied by parents. However, parental supply was not associated with bingeing, and those supplied alcohol by parents typically consumed fewer drinks per occasion (incidence rate ratio 0.86, 95% CI 0.77-0.96) than adolescents supplied only from other sources. Adolescents obtaining alcohol from non-parental sources had increased odds of drinking whole beverages (OR 2.53, 95% CI 1.86-3.45) and bingeing (OR 3.51, 95% CI 2.53-4.87). CONCLUSIONS Parental supply of alcohol to adolescents was associated with increased risk of drinking, but not bingeing. These parentally-supplied children also consumed fewer drinks on a typical drinking occasion. Adolescents supplied alcohol from non-parental sources had greater odds of drinking and bingeing. Further follow-up is necessary to determine whether these patterns continue, and to examine alcohol-related harm trajectories. Parents should be advised that supply of alcohol may increase children's drinking.
Collapse
Affiliation(s)
- R P Mattick
- National Drug and Alcohol Research Centre,University of New South Wales (UNSW) Australia,Sydney, NSW 2052,Australia
| | - M Wadolowski
- The Kirby Institute,University of New South Wales (UNSW) Australia,Sydney, NSW 2052,Australia
| | - A Aiken
- National Drug and Alcohol Research Centre,University of New South Wales (UNSW) Australia,Sydney, NSW 2052,Australia
| | - P J Clare
- National Drug and Alcohol Research Centre,University of New South Wales (UNSW) Australia,Sydney, NSW 2052,Australia
| | - D Hutchinson
- School of Psychology,Deakin University,Melbourne, VIC 3125,Australia
| | - J Najman
- Queensland Alcohol and Drug Research and Education Centre,University of Queensland,Brisbane, QLD 4072,Australia
| | - T Slade
- National Drug and Alcohol Research Centre,University of New South Wales (UNSW) Australia,Sydney, NSW 2052,Australia
| | - R Bruno
- School of Psychology,University of Tasmania,Hobart, TAS 7000,Australia
| | - N McBride
- National Drug Research Institute,Curtin University,GPO Box U1987,Perth, WA 6845,Australia
| | - L Degenhardt
- National Drug and Alcohol Research Centre,University of New South Wales (UNSW) Australia,Sydney, NSW 2052,Australia
| | - K Kypri
- Centre for Clinical Epidemiology and Biostatistics,School of Medicine and Public Health,University of Newcastle,Newcastle, NSW 2308,Australia
| |
Collapse
|
36
|
Aghemo A, Bruno R, Colombo M, Medagli M, Puoti M, Rizzardini G, Fagiuoli S. Treatment of patients with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network. Eur Rev Med Pharmacol Sci 2016; 20:17-19. [PMID: 28083863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The arrival of potent directly acting antivirals (DAAs) for the treatment of chronic Hepatitis C virus (HCV) infection was a challenge for the regional health system of the Lombardia Region. Lombardia represents roughly 8% of the Italian territory but includes nearly 16% of the Italian population. In 2014, nearly 37,600 HCV patients were routinely followed-up in liver centers across the region; nearly 16,000 were classified as having advanced fibrosis or cirrhosis (Metavir F3-F4). The creation of a regional network was necessary to ensure uniformity in treatment access and treatment management. The first database analysis of the Lombardia Hepatitis Network was conducted in January 2016, and included data on 2432 patients who had received treatment from December 2014 to December 2015. The most prevalent HCV genotypes were HCV-1 found in 63% and HCV-3 found in 17%. Overall 90.4% patients achieved an SVR, SVR rates were 92.9% in HCV-1, 89.3% in HCV-2, 81.1% in HCV-3 and 88.9% in HCV-4.
Collapse
Affiliation(s)
- A Aghemo
- Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
| | | | | | | | | | | | | |
Collapse
|
37
|
Carbone A, Amenduni T, Bruno R. Hashimoto's encephalopathy (HE): an under diagnosed autoimmune-mediated encephalopathy. Endocrine 2016; 54:572-573. [PMID: 26649860 DOI: 10.1007/s12020-015-0806-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2015] [Accepted: 11/07/2015] [Indexed: 10/22/2022]
Affiliation(s)
- A Carbone
- Endocrine Unit, Tinchi Hospital, Pisticci, Italy
| | - T Amenduni
- Endocrine Unit, Tinchi Hospital, Pisticci, Italy
| | - R Bruno
- Endocrine Unit, Tinchi Hospital, Pisticci, Italy.
| |
Collapse
|
38
|
Pedrazzoli P, Zuccaro V, Pagani A, Puoti M, Gaeta G, Pinto C, Taliani G, Baldanti F, Cinieri S, Bruno R. Management of hepatitis C positive patients undergoing active treatment for malignancies: a position paper from the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Malattie Infettive e Tropicali (SIMIT). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw345.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Han K, Claret L, Piao Y, Hegde P, Joshi A, Powell JR, Jin J, Bruno R. Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A. CPT Pharmacometrics Syst Pharmacol 2016; 5:352-8. [PMID: 27404946 PMCID: PMC4961078 DOI: 10.1002/psp4.12064] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Accepted: 01/26/2016] [Indexed: 12/31/2022]
Abstract
To simulate clinical trials to assess overall survival (OS) benefit of bevacizumab in combination with chemotherapy in selected patients with gastric cancer (GC), a modeling framework linking OS with tumor growth inhibition (TGI) metrics and baseline patient characteristics was developed. Various TGI metrics were estimated using TGI models and data from two phase III studies comparing bevacizumab plus chemotherapy vs. chemotherapy as first‐line therapy in 976 GC patients. Time‐to‐tumor‐growth (TTG) was the best TGI metric to predict OS. TTG, Eastern Cooperative Oncology Group (ECOG) score, albumin level, and Asian ethnicity were significant covariates in the final OS model. The model correctly predicted a decreased hazard ratio favorable to bevacizumab in patients with high baseline plasma VEGF‐A above the median of 113.4 ng/L. Based on trial simulations, in trials enrolling patients with elevated baseline plasma VEGF‐A (500 patients per arm), the expected hazard ratio was 0.82 (95% prediction interval: 0.70–0.95), independent of ethnicity.
Collapse
Affiliation(s)
- K Han
- Genentech Inc, Clinical Pharmacology, South San Francisco, California, USA
| | - L Claret
- Pharsight Consulting Services, Pharsight, a Certara Company, Marseille, France
| | - Y Piao
- Roche Product Development in Asia Pacific, Shanghai, China
| | - P Hegde
- Genentech Inc, Biomarker, South San Francisco, California, USA
| | - A Joshi
- Genentech Inc, Clinical Pharmacology, South San Francisco, California, USA
| | - J R Powell
- Pharmaceutical Research and Early Development (pRED), Roche, Beijing, China
| | - J Jin
- Genentech Inc, Clinical Pharmacology, South San Francisco, California, USA
| | - R Bruno
- Pharsight Consulting Services, Pharsight, a Certara Company, Marseille, France
| |
Collapse
|
40
|
Bruno R, Alì G, Giannini R, Lucchi M, Melfi F, Mussi A, Fontanini G. 210P: Digital gene expression profiling to separate malignant pleural mesothelioma from benign reactive mesothelial hyperplasia. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30317-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
Craxì L, Sacchini D, Refolo P, Minacori R, Daloiso V, Ricci G, Bruno R, Cammà C, Cicchetti A, Gasbarrini A, Spagnolo AG. Prioritization of high-cost new drugs for HCV: making sustainability ethical. Eur Rev Med Pharmacol Sci 2016; 20:1044-1051. [PMID: 27049255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Hepatitis C virus (HCV) infection is a major health problem worldwide. Chronic HCV infection may in the long run cause cirrhosis, hepatic decompensation and hepatocellular carcinoma, with an ultimate disease burden of at least 350,000 deaths per year worldwide. The new generation of highly effective direct acting antivirals (DAA) to treat HCV infection brings major promises to infected patients in terms of exceedingly high rates of sustained virological response (SVR) but also of tolerability, allowing even the sickest patients to be treated. Even in the face of the excellent safety and efficacy and wide theoretical applicability of these regimens, their introduction is currently facing cost and access issues denying their use to many patients in need. Health systems in all countries are facing a huge problem of distributive justice, since while they should guarantee individual rights, among which the right to health in its broader sense, therefore not limited to healing, but extended to quality of life, they must also grant equal access to the healthcare resources and keep the distribution system sustainable. In the face of a disease with a relatively unpredictable course, where many but not of all chronically infected will eventually die of liver disease, selective allocation of this costly resource is debatable. In most countries the favorite solution has been a stratification of patients for prioritization of treatment, which means allowing Interferon-free DAA treatment only in patients with advanced fibrosis or cirrhosis, while keeping on hold persons with lesser stages of liver disease. In this report, we will perform an ethical assessment addressing the issues linked to access to new therapies, prioritization and eligibility criteria, analyzing the meaning of the term "distributive justice" and the different approaches that can guide us (individualistic libertarianism, social utilitarianism and egalitarianism) on this specific matter. Even if over time the price of new DAA will be reduced through competition and eventual patent expiration, the phenomenon of high drug costs will go on in the next decades and we need adequate tools to face the problems of distributive justice that come with it.
Collapse
Affiliation(s)
- L Craxì
- Institute of Bioethics and Medical Humanities, "A. Gemelli" School of Medicine, Università Cattolica del Sacro Cuore, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Jonsson F, Ou Y, Claret L, Siegel D, Jagannath S, Vij R, Badros A, Aggarwal S, Bruno R. A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use. CPT Pharmacometrics Syst Pharmacol 2015; 4:711-9. [PMID: 26904385 PMCID: PMC4759707 DOI: 10.1002/psp4.12044] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/29/2015] [Accepted: 09/27/2015] [Indexed: 11/10/2022]
Abstract
Change in tumor size estimated using longitudinal tumor growth inhibition (TGI) modeling is an early predictive biomarker of clinical outcomes for multiple cancer types. We present the application of TGI modeling for subjects with multiple myeloma (MM). Longitudinal time course changes in M‐protein data from relapsed and/or refractory MM subjects who received single‐agent carfilzomib in phase II studies (n = 456) were fit to a TGI model. The tumor growth rate estimate was similar to that of other anti‐myeloma agents, indicating that the model is robust and treatment‐independent. An overall survival model was subsequently developed, which showed that early change in tumor size (ECTS) at week 4, Eastern Cooperative Oncology Group performance status (ECOG PS), hemoglobin, sex, percent bone marrow cell involvement, and number of prior regimens were significant independent predictors for overall survival (P < 0.001). ECTS based on M‐protein modeling could be an early biomarker for survival in MM following exposure to single‐agent carfilzomib.
Collapse
Affiliation(s)
- F Jonsson
- Pharsight, a Certara company St. Louis Missouri USA
| | - Y Ou
- Onyx Pharmaceuticals, Inc., an Amgen subsidiary South San Francisco California USA
| | - L Claret
- Pharsight, a Certara company St. Louis Missouri USA
| | - D Siegel
- John Theurer Cancer Center Hackensack New Jersey USA
| | - S Jagannath
- Mount Sinai Medical Center New York New York USA
| | - R Vij
- Washington University School of Medicine St. Louis Missouri USA
| | - A Badros
- Greenebaum Cancer Center University of Maryland Baltimore Maryland USA
| | - S Aggarwal
- Onyx Pharmaceuticals, Inc., an Amgen subsidiary South San Francisco California USA
| | - R Bruno
- Pharsight, a Certara company St. Louis Missouri USA
| |
Collapse
|
43
|
Hoban B, Larance B, Gisev N, Nielsen S, Cohen M, Bruno R, Shand F, Lintzeris N, Hall W, Farrell M, Degenhardt L. The use of paracetamol (acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. Int J Clin Pract 2015; 69:1366-76. [PMID: 26268890 DOI: 10.1111/ijcp.12716] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Accepted: 07/22/2015] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND The regular use of simple analgesics in addition to opioids such as paracetamol (or acetaminophen) is recommended for persistent pain to enhance analgesia. Few studies have examined the frequency and doses of paracetamol among people with chronic non-cancer pain including use above the recommended maximum daily dose. AIMS To assess (i) the prevalence of paracetamol use among people with chronic non-cancer pain prescribed opioids, (ii) assess the prevalence of paracetamol use above the recommended maximum daily dose and (iii) assess correlates of people who used paracetamol above the recommended maximum daily dose including: age, gender, income, education, pain severity and interference, use of paracetamol/opioid combination analgesics, total opioid dose, depression, anxiety, pain self-efficacy or comorbid substance use, among people prescribed opioids for chronic non-cancer pain. METHODS This study draws on baseline data collected for the Pain and Opioids IN Treatment (POINT) study and utilises data from 962 interviews and medication diaries. The POINT study is national prospective cohort of people with chronic non-cancer pain prescribed opioids. Participants were recruited from randomly selected pharmacies across Australia. RESULTS Sixty-three per cent of the participants had used paracetamol in the past week (95% CI = 59.7-65.8). Among the paracetamol users 22% (95% CI = 19.3-24.6) had used paracetamol/opioid combination analgesics and 4.8% (95% CI = 3.6-6.3) had used paracetamol above the recommended maximum daily dose (i.e. > 4000 mg/day). Following binomial logistic regression (χ(2) = 25.98, df = 10, p = 0.004), people who had taken above the recommended maximum daily dose were less likely to have low income (AOR = 0.52, 95% CI = 0.27-0.99), more likely to use paracetamol/opioid combination analgesics (AOR = 2.01, 95% CI = 1.02-3.98) and more likely to take a higher opioid dose (AOR = 1.00, 95% CI = 1.00-1.01). CONCLUSION The majority of people with chronic non-cancer pain prescribed opioids report using paracetamol appropriately. High income, use of paracetamol/opioid combination analgesics and higher opioid dose were independently associated with paracetamol use above the recommended maximum daily dose.
Collapse
Affiliation(s)
- B Hoban
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
| | - B Larance
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
| | - N Gisev
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
| | - S Nielsen
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
- The Langton Centre, South East Sydney Local Health District (SESLHD), Drug and Alcohol Services, Surry Hills, NSW, Australia
| | - M Cohen
- St Vincent's Clinical School, UNSW Australia, Darlinghurst, NSW, Australia
| | - R Bruno
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
- School of Psychology, University of Tasmania, Hobart, TAS, Australia
| | - F Shand
- Black Dog Institute, Prince of Wales Hospital, Randwick, NSW, Australia
| | - N Lintzeris
- The Langton Centre, South East Sydney Local Health District (SESLHD), Drug and Alcohol Services, Surry Hills, NSW, Australia
- Sydney Medical School, Sydney University, Camperdown, NSW, Australia
| | - W Hall
- Centre for Youth Substance Abuse Research, University of Queensland, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
| | - M Farrell
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
| | - L Degenhardt
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
- School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia
- Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, VIC, Australia
- Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA
| |
Collapse
|
44
|
Adhikari L, Zank GP, Bruno R, Telloni D, Hunana P, Dosch A, Marino R, Hu Q. The transport of low-frequency turbulence in the super-Alfvénic solar wind. ACTA ACUST UNITED AC 2015. [DOI: 10.1088/1742-6596/642/1/012001] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
45
|
Mendoza L, Piquemal D, Lejeune JP, Vander Heyden L, Noguier F, Bruno R, Sandersen C, Serteyn D. Age-dependent expression of osteochondrosis-related genes in equine leukocytes. Vet Rec Open 2015; 2:e000058. [PMID: 26392886 PMCID: PMC4567144 DOI: 10.1136/vetreco-2014-000058] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Revised: 11/25/2014] [Accepted: 12/16/2014] [Indexed: 11/04/2022] Open
Abstract
INTRODUCTION Osteochondrosis (OC) is a developmental disease in horses which has a significant impact on the horse's welfare and performance. The early disturbance in the process of endochondral ossification progresses to inflammatory and repair processes in older horses. Previously, differentially expressed genes in leukocytes of OC-affected horses have been identified. The aim of the present study is to detect age-related changes in these differentially expressed genes. MATERIALS AND METHODS The expression of OC-related genes was analysed by real-time PCR and subsequent statistical analysis (ΔΔCT) in the leukocytes of 135 Belgian Warmblood horses divided into three different age groups: <12 months (n=47), 18-24 months (n=50) >30 months (n=38). RESULTS Relative expression of genes of horses less than 12 months of age showed significant induction of the genes MGAT4A, PRKCG, MHCI, ApoB, ApoB3G, B4GALT6 and a significantly lower expression of the genes OAS3. Horses of 18-24 months of age, showed a significantly higher expression of the genes TBC1D9, MGAT4A, IFIH1, MHCIIa and MMP1. Horses of more than 30 months of age showed a significantly higher expression of the genes MGAT4A, HP, SECTM1 compared with their age-matched control groups. CONCLUSIONS The study demonstrates that OC-related genes are differentially expressed in horses of different ages compared with their age-matched controls. Some of the genes may be implicated in cell signalling and differentiation as well as carbohydrate and lipid metabolism and inflammation. However, the causal relationship between the differentially expressed genes and the development and progression of the OC lesions needs to be determined.
Collapse
Affiliation(s)
- L Mendoza
- University of Liège , Liège , Belgium ; Equine Research and Development Center , Mont-le-Soie , Belgium
| | - D Piquemal
- Computational Biology Institute (IBC) , France ; University of Montpellier2 , Montpellier , France ; Acobiom , Montpellier , France
| | - J P Lejeune
- Equine Research and Development Center , Mont-le-Soie , Belgium
| | - L Vander Heyden
- Equine Research and Development Center , Mont-le-Soie , Belgium
| | | | - R Bruno
- Acobiom , Montpellier , France
| | | | - D Serteyn
- University of Liège , Liège , Belgium ; Equine Research and Development Center , Mont-le-Soie , Belgium
| |
Collapse
|
46
|
Faconti L, Bruno R, Ghiadoni L, Taddei S, Virdis A. Ventricular and Vascular Stiffening in Aging and Hypertension. Curr Hypertens Rev 2015; 11:100-9. [DOI: 10.2174/1573402111666150529131208] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2015] [Accepted: 05/28/2015] [Indexed: 11/22/2022]
|
47
|
Adhikari L, Zank GP, Bruno R, Telloni D, Hunana P, Dosch A, Marino R, Hu Q. THE TRANSPORT OF LOW-FREQUENCY TURBULENCE IN ASTROPHYSICAL FLOWS. II. SOLUTIONS FOR THE SUPER-ALFVÉNIC SOLAR WIND. ACTA ACUST UNITED AC 2015. [DOI: 10.1088/0004-637x/805/1/63] [Citation(s) in RCA: 79] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
48
|
Chiari M, Prosperi A, Faccin F, Avisani D, Cerioli M, Zanoni M, Bertoletti M, Moreno AM, Bruno R, Monaco F, Farioli M, Lelli D, Lavazza A. West Nile Virus Surveillance in the Lombardy Region, Northern Italy. Transbound Emerg Dis 2015; 62:343-9. [PMID: 25958924 DOI: 10.1111/tbed.12375] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2014] [Indexed: 01/09/2023]
Abstract
In 2013, the circulation of West Nile virus (WNV) was detected in the Lombardy region and the following year a surveillance programme was activated with the aim of early identification of the viral distribution in mosquitoes and wild birds. A total of 50 959 Culex spp. mosquitoes grouped in six hundred and forty-seven pools as well as 1400 birds were screened by RT-PCR for the presence of West Nile virus leading to the identification of the viral genome in 32 mosquito pools and 13 wild birds. The surveillance was able to detect the WNV circulation on an average of 42 days (CI 95% 29.98-53.86; Student's t-distribution) before the occurrence of human West Nile disease (WND) cases in the same area. These results demonstrate the presence of WNV in the Lombardy region and confirm entomological and wild birds surveillance as an effective measure for the early identification of WNV circulation in infected areas, thus providing a useful and cost-effective tool for the public health authorities in the application of measures to prevent human infection.
Collapse
Affiliation(s)
- M Chiari
- Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", Brescia, Italy
| | - A Prosperi
- Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", Brescia, Italy
| | - F Faccin
- Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", Brescia, Italy
| | - D Avisani
- Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", Brescia, Italy
| | - M Cerioli
- Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", Brescia, Italy
| | - M Zanoni
- Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", Brescia, Italy
| | - M Bertoletti
- Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", Brescia, Italy
| | - A M Moreno
- Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", Brescia, Italy
| | - R Bruno
- Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise ''G. Caporale'', Teramo, Italy
| | - F Monaco
- Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise ''G. Caporale'', Teramo, Italy
| | - M Farioli
- U.O. Veterinaria, Regione Lombardia, Milano, Italy
| | - D Lelli
- Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", Brescia, Italy
| | - A Lavazza
- Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini", Brescia, Italy
| |
Collapse
|
49
|
Nielsen S, Roxburgh A, Bruno R, Lintzeris N, Jefferson A, Degenhardt L. Changes in non-opioid substitution treatment episodes for pharmaceutical opioids and heroin from 2002 to 2011. Drug Alcohol Depend 2015; 149:212-9. [PMID: 25707708 DOI: 10.1016/j.drugalcdep.2015.02.004] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2014] [Revised: 01/27/2015] [Accepted: 02/03/2015] [Indexed: 01/28/2023]
Abstract
BACKGROUND There has been a well-documented increase in the non-medical use of pharmaceutical opioids (PO) worldwide. However, there has been little detailed examination of treatment demand, or the characteristics of those presenting for treatment, particularly for treatments other than opioid substitution. METHODS Data from closed drug and alcohol treatment episodes from the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS-NMDS, representing non-opioid substitution treatment) in Australia for 2002-2003 to 2010-2011 were examined. In the four jurisdictions where detailed data were available, episodes where heroin was the principal drug of concern were compared to episodes for the four most frequently reported pharmaceutical opioids (morphine, codeine, fentanyl and oxycodone). RESULTS In 2002-2003, most (93%) opioid treatment was related to heroin with seven percent of all opioid treatment episodes reporting a PO as the principal drug of concern. In 2010-2011, 20% of all opioid treatment episodes were attributed to POs. Distinct changes over time were observed for different opioids. There was an increase in the average age at the start of treatment for heroin and oxycodone episodes, and a reduction in the proportion of females for codeine episodes, with 67% in 2002-2003 compared with 44% in 2010-2011. Codeine and oxycodone episodes had the lowest current or past injection rates. CONCLUSIONS Clear differences were observed over time and between different opioids. Monitoring these emerging patterns will be important to inform treatment needs, particularly in light of different patterns of poly drug use, different routes of administration and changing demographic characteristics.
Collapse
Affiliation(s)
- S Nielsen
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales 2052, Australia; Drug and Alcohol Services, South Eastern Sydney Local Health District, 591 South Dowling St, Surry Hills 2010, Australia.
| | - A Roxburgh
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales 2052, Australia
| | - R Bruno
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales 2052, Australia; School of Medicine, University of Tasmania, Level 1, Medical Science 1, 17 Liverpool Street, Hobart 7000, Australia
| | - N Lintzeris
- Drug and Alcohol Services, South Eastern Sydney Local Health District, 591 South Dowling St, Surry Hills 2010, Australia; University of Sydney, Department of Addiction Medicine, Missenden Road, Camperdown 2006, Australia
| | - A Jefferson
- Tobacco, Alcohol and Other Drugs Unit, Australian Institute of Health and Welfare, 1 Thynne Street, Fern Hill Park, Bruce 2617, Australia
| | - L Degenhardt
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales 2052, Australia
| |
Collapse
|
50
|
Novati S, Sacchi P, Cima S, Zuccaro V, Columpsi P, Pagani L, Filice G, Bruno R. General issues on microbial translocation in HIV-infected patients. Eur Rev Med Pharmacol Sci 2015; 19:866-878. [PMID: 25807441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The lumen of the gastrointestinal tract is home to an enormous quantity of different bacterial species that thrive in an often symbiotic relationship with the host. It is the principal source of microbial products because of its massive bacterial load. Injury to the immune component of the gastrointestinal mucosal surface, along with damage to the intestinal epithelial microenvironment with its antimicrobial functions, may affect systemic immune activation during the chronic phase of HIV infection through the increased translocation of luminal microbial products. Moreover, microbial translocation, which is defined as "the passage of both viable and nonviable microbes and microbial products such as endotoxin across anatomically intact intestinal barrier", may be a fundamental mechanism through which HIV accelerates progression of chronic viral hepatitis. Improvements in the tools available to microbiota research, and especially advancement of our knowledge in this area may help us in controlling the evolution of HIV disease, although population complexity and diversity between individuals make this challenging.
Collapse
Affiliation(s)
- S Novati
- Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
| | | | | | | | | | | | | | | |
Collapse
|